Brief Review of Interventional Versus Medical Therapy for Unruptured Brain Arteriovenous Malformations: Multicentre, Non-Randomised Controlled Trial— Mohr 2020

This is a brief audio review. In the article Medical management with interventional therapy versus medical management alone for unruptured brain arteriovenous malformations (ARUBA): final follow-up of a multicenter, non-randomized controlled trial published, 2020 by Mohr and Colleagues, The outcomes and key points are as noted: The ARUBA trial is known for studying and documenting the outcomes of patients with arteriovenous malformations who either had medical management solely or medical management with surgical intervention. After a follow up time of 50.4 months the incidence of stroke and or death was higher in the interventional group. Medical management resulted in 15 death or stroke out of 110 patients; Interventional therapy resulted in 41 deaths or stroke out of 116. Adverse events were observed less often in patients allocated to medical management compared with interventional therapy (283 vs 369, 95% CI -30.33 to -9.19). This was a Randomized control trial, nonblinded, multicenter with 226 patients who were Patients with arteriovenous malformation.

Mohr JP, Overbey JR, Hartmann A, Kummer RV, Al-Shahi Salman R, Kim H, van der Worp HB, Parides MK, Stefani MA, Houdart E, Libman R, Pile-Spellman J, Harkness K, Cordonnier C, Moquete E, Biondi A, Klijn CJM, Stapf C, Moskowitz AJ; ARUBA co-investigators. Medical management with interventional therapy versus medical management alone for unruptured brain arteriovenous malformations (ARUBA): final follow-up of a multicentre, non-blinded, randomised controlled trial. Lancet Neurol. 2020 Jul;19(7):573-581. doi: 10.1016/S1474-4422(20)30181-2. PMID: 32562682.